FROM ONCOLOGIST TO SURGEON - GENETICS IN COLORECTAL METASTASIS FOR SURGEONS
Authors:
- Marília Polo Mingueti e SilvaMSMarília Polo Mingueti e Silva
- Jorge SabbagaJSJorge Sabbaga
- Henry Luiz NajmanHNHenry Luiz Najman
- Carlos David Carvalho NascimentoCNCarlos David Carvalho Nascimento
- Ricardo Lemos Cotta-PereiraRCRicardo Lemos Cotta-Pereira
- João Eduardo Leal NicoluzziJNJoão Eduardo Leal Nicoluzzi
- Maria Ignez BraghiroliMBMaria Ignez Braghiroli
Open Access
- 1 January 2024
- journal article
- review article
- Published by FapUNIFESP (SciELO) in ABCD. Arquivos Brasileiros de Cirurgia Digestiva (São Paulo)
- Vol. 37, e1869
Abstract
Colorectal cancer (CRC) is a common disease, with incidence in Brazil of 45,630 new cases per 100,000 inhabitants between 2023-2025. Risk factors for CRC can be evaluated between environmental and hereditary and their mode of presentation are classified as sporadic, inherited and familial. Sporadic disease is characterized by the absence of a family history and accounts for approximately 70% of all colorectal cancers, being more common over 50 years of age, with dietary and environmental factors implicated in its pathogenesis. Sporadic disease is characterized by the absence of a family history and accounts for approximately 70% of all colorectal cancers, being more common over 50 years of age, with dietary and environmental factors implicated in its pathogenesis. The percentage of patients with a true hereditary genetic predisposition is less than 10%, and these are related to the presence or absence of colonic polyps as an important manifestation of the disease. Non-polyposis diseases are known as hereditary non-polypomatous colorectal cancer (HNPCC) or Lynch syndrome, and polyposis diseases are familial adenomatous polyposis (FAP), MUTYH-associated polyposis (MAP), and hamartomatous polyposis syndromes (e.g., Peutz-Jeghers, juvenile polyposis, phosphatase and tensin homologue - PTEN, Cowden syndrome). These diseases are linked to a high risk of developing cancer. With the development of treatments in metastatic disease and the use of targeted therapies and their biomarkers, it was possible to evaluate them within clinical studies both in the primary tumor and in the correspondence of metastases.Keywords
This publication has 20 references indexed in Scilit:
- Deleterious Effect of RAS and Evolutionary High-risk TP53 Double Mutation in Colorectal Liver MetastasesAnnals of Surgery, 2019
- Biomarker concordance between primary colorectal cancer and its metastasesEBioMedicine, 2019
- Association of BRAF Mutations With Survival and Recurrence in Surgically Treated Patients With Metastatic Colorectal Liver CancerJAMA Surgery, 2018
- Molecular pathological classification of colorectal cancerVirchows Archiv, 2016
- The consensus molecular subtypes of colorectal cancerNature Medicine, 2015
- Comprehensive molecular characterization of human colon and rectal cancerNature, 2012
- Comparative lesion sequencing provides insights into tumor evolutionProceedings of the National Academy of Sciences, 2008
- Classification of colorectal cancer based on correlation of clinical, morphological and molecular featuresHistopathology, 2006
- CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancerNature Genetics, 2006
- A genetic model for colorectal tumorigenesisCell, 1990